CRISPR Slashes ‘Bad Cholesterol’ Levels by 95 Percent in Early Results
Singularity Hub
|
November 27, 2025
X min read
Singularity Hub
|
November 27, 2025
Share on Social
More like this
News
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
February 17, 2026
Read Now
Press
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
February 17, 2026
Read Now
News
Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction
January 20, 2026
Read Now
Press
Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction
January 20, 2026
Read Now
